These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 35396830

  • 1. Two cases with fulminant type 1 diabetes that developed long after cessation of immune checkpoint inhibitor treatment.
    Hatayama S, Kodama S, Kawana Y, Otake S, Sato D, Horiuchi T, Takahashi K, Kaneko K, Imai J, Katagiri H.
    J Diabetes Investig; 2022 Aug; 13(8):1458-1460. PubMed ID: 35396830
    [Abstract] [Full Text] [Related]

  • 2. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
    Yaura K, Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z.
    Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
    [Abstract] [Full Text] [Related]

  • 3. Type 1 diabetes associated with immune checkpoint inhibitors for malignant melanoma: A case report and review of 8 cases.
    Ishiguro A, Ogata D, Ohashi K, Hiki K, Yamakawa K, Jinnai S, Tsutsui K, Takahashi A, Namikawa K, Yamazaki N.
    Medicine (Baltimore); 2022 Sep 02; 101(35):e30398. PubMed ID: 36107581
    [Abstract] [Full Text] [Related]

  • 4. Case report: Strong GAD antibody positivity and type 1 diabetes-HLA-susceptible haplotype-DRB1*04:05-DQB1*04:01 in a Japanese patient with immune checkpoint inhibitor-induced type 1 diabetes.
    Yabuki S, Hirai H, Moriya C, Kusano Y, Hasegawa T.
    Front Endocrinol (Lausanne); 2024 Sep 02; 15():1407192. PubMed ID: 38841300
    [Abstract] [Full Text] [Related]

  • 5. Nivolumab-induced fulminant type 1 diabetes with precipitous fall in C-peptide level.
    Miyauchi M, Toyoda M, Zhang J, Hamada N, Yamawaki T, Tanaka J, Harada K, Kashizaki F, Fukagawa M.
    J Diabetes Investig; 2020 May 02; 11(3):748-749. PubMed ID: 31587459
    [Abstract] [Full Text] [Related]

  • 6. Immune checkpoint inhibitor-related type 1 diabetes mellitus which develops long after treatment discontinuation: a case report and review of literature.
    Obata Y, Takemoto M, Sakaue TA, Kawata S, Mukai K, Miyashita K, Kozawa J, Nishizawa H, Shimomura I.
    Diabetol Int; 2024 Jul 02; 15(3):605-610. PubMed ID: 39101180
    [Abstract] [Full Text] [Related]

  • 7. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
    Nakako S, Nakashima Y, Okamura H, Tani Y, Ueda T, Makuuchi Y, Kuno M, Takakuwa T, Nishimoto M, Koh H, Nakamae H, Hino M.
    Immunotherapy; 2022 Feb 02; 14(2):101-105. PubMed ID: 34758635
    [Abstract] [Full Text] [Related]

  • 8. Immune checkpoint inhibitor-induced refractory polyarthritis rapidly improved by sarilumab and monitoring with joint ultrasonography: A case report.
    Abe K, Ishikawa Y, Fujiwara M, Yukawa H, Yanagihara T, Takei S, Arioka H, Kita Y.
    Medicine (Baltimore); 2022 Jan 14; 101(2):e28428. PubMed ID: 35029182
    [Abstract] [Full Text] [Related]

  • 9. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
    Grimmelmann I, Momma M, Zimmer L, Hassel JC, Heinzerling L, Pföhler C, Loquai C, Ruini C, Utikal J, Thoms KM, Kähler KC, Eigentler T, Herbst RA, Meier F, Debus D, Berking C, Kochanek C, Ugurel S, Gutzmer R, German Dermatooncology Group (DeCOG).
    Eur J Cancer; 2021 May 14; 149():1-10. PubMed ID: 33812141
    [Abstract] [Full Text] [Related]

  • 10. Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC.
    Matsuura N, Koh G, Konishi C, Minamino S, Takahara Y, Harada H, Kodama K, Emoto M.
    Cancer Immunol Immunother; 2018 Sep 14; 67(9):1417-1424. PubMed ID: 29995236
    [Abstract] [Full Text] [Related]

  • 11. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C, Westeel V.
    Cochrane Database Syst Rev; 2021 Apr 30; 4(4):CD013257. PubMed ID: 33930176
    [Abstract] [Full Text] [Related]

  • 12. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C.
    J Immunother Cancer; 2017 Apr 30; 5():40. PubMed ID: 28515940
    [Abstract] [Full Text] [Related]

  • 13. Incidence and risk factors of immune-related adverse events induced by immune checkpoint inhibitors among older adults with non-small cell lung cancer.
    Rong Y, Bentley JP, Bhattacharya K, Yang Y, Chang Y, Earl S, Ramachandran S.
    Cancer Med; 2024 Jan 30; 13(1):e6879. PubMed ID: 38164655
    [Abstract] [Full Text] [Related]

  • 14. Fulminant Type 1 Diabetes Mellitus Caused by Long-Term Nivolumab Administration Followed by Nivolumab plus Cabozantinib Combination.
    Homma T, Yoshida N, Tanaka K, Isemura M, Torii S, Kinoshita T, Esaki H, Sakakibara T, Takimoto N.
    Chemotherapy; 2023 Jan 30; 68(1):44-47. PubMed ID: 36327909
    [Abstract] [Full Text] [Related]

  • 15. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, Guarneri V, Aprile G, Conte P, Bonanno L.
    Oncologist; 2019 Aug 30; 24(8):1128-1136. PubMed ID: 31015312
    [Abstract] [Full Text] [Related]

  • 16. Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients.
    Smith DA, Radzinsky E, Tirumani SH, Guler E, Petraszko A, Kikano E, Hoimes CJ, Ramaiya NH.
    AJR Am J Roentgenol; 2021 Sep 30; 217(3):613-622. PubMed ID: 33295801
    [Abstract] [Full Text] [Related]

  • 17. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study.
    Okada N, Matsuoka R, Sakurada T, Goda M, Chuma M, Yagi K, Zamami Y, Nishioka Y, Ishizawa K.
    Sci Rep; 2020 Aug 13; 10(1):13773. PubMed ID: 32792640
    [Abstract] [Full Text] [Related]

  • 18. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes.
    Kotwal A, Haddox C, Block M, Kudva YC.
    BMJ Open Diabetes Res Care; 2019 Aug 13; 7(1):e000591. PubMed ID: 30899528
    [Abstract] [Full Text] [Related]

  • 19. Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study.
    Miura K, Sano Y, Niho S, Kawasumi K, Mochizuki N, Yoh K, Matsumoto S, Zenke Y, Ikeda T, Nosaki K, Kirita K, Udagawa H, Goto K, Kawasaki T, Hanada K.
    Thorac Cancer; 2021 Jul 13; 12(13):1983-1994. PubMed ID: 33990133
    [Abstract] [Full Text] [Related]

  • 20. Immune Checkpoint Inhibitor-related Guillain-Barré Syndrome: A Case Series and Review of the Literature.
    Janssen JBE, Leow TYS, Herbschleb KH, Gijtenbeek JMM, Boers-Sonderen MJ, Gerritsen WR, Westdorp H.
    J Immunother; 2021 Sep 01; 44(7):276-282. PubMed ID: 33758147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.